Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N. Krop IE, et al. Among authors: shah j. J Clin Oncol. 2022 Feb 10;40(5):438-448. doi: 10.1200/JCO.21.00896. Epub 2021 Dec 10. J Clin Oncol. 2022. PMID: 34890214 Free PMC article. Clinical Trial.
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Emens LA, et al. Among authors: shah j. Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4. Lancet Oncol. 2020. PMID: 33002436 Clinical Trial.
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS. Hudis C, et al. Among authors: shah j. Breast Cancer Res. 2013 Nov 19;15(6):R110. doi: 10.1186/bcr3577. Breast Cancer Res. 2013. PMID: 24252402 Free PMC article. Clinical Trial.
Skull base surgery for malignant tumors: The 2nd international collaborative study (1995-2015).
Shah JP, Levyn H, Valero C, Adilbay D, Eagan A, Zheng J, Gonen M, Cohen M, Patel S, Ganly I, Pai P, Castelnuovo P, Gao FJ, Piazza C, Nicolai P, Panizza B, Bowman J, Barnett C, Kowalski LP, Toledo R, Fliss DM, DeAlmeida J, Witterick I, Herman P, Fontanella W, Aniceto GS, Hosal S, Ozer S, Iyer S, Harvey R, Leemans CR, Hendrickx JJ, Figari M, Boccalatte L, Nibu KI, Clarke P, Rennie C, Ming ZY, Cernea C, Goncalves S, Schlosser R, Dias F, Sargi Z, Ahmed S, Golusinski W, Kim SH, Su SY, Raza SM, DeMonte F, Hanna E. Shah JP, et al. Head Neck. 2024 May 21. doi: 10.1002/hed.27746. Online ahead of print. Head Neck. 2024. PMID: 38770972
Reply to Yamamoto.
Srinu D, Sharma V, Shah J. Srinu D, et al. Among authors: shah j. Am J Gastroenterol. 2024 May 21. doi: 10.14309/ajg.0000000000002848. Online ahead of print. Am J Gastroenterol. 2024. PMID: 38770937 No abstract available.
A Contemporary Analysis of Mental Well-being Among Living Donor Kidney Applicants.
Levea SL, Prasadh JG, Wang BK, Salcedo-Betancourt JD, Matevish L, Sanchez Vivaldi J, Lieber SR, Shah JA, Hwang CS, Wojciechowski D, Vagefi PA, Patel MS. Levea SL, et al. Among authors: shah ja. Transplant Direct. 2024 May 15;10(6):e1631. doi: 10.1097/TXD.0000000000001631. eCollection 2024 Jun. Transplant Direct. 2024. PMID: 38757049 Free PMC article.
4,143 results